Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

View Eli Lilly and Company (LLY) current and estimated P/E ratio data provided by Seeking Alpha.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 597.82% and currently trading at $922.59.The company has been around since 1876 and ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

We recently compiled a list of Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025. In this article, we are going to ...

Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the medication. By Dani Blum With high demand for drugs ...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use ... will be available in the next few weeks, the company said. Eczema, also known as atopic dermatitis ...

Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to the career path of his predecessor, Anat Ashkenazi, who also spent two ...

We recently compiled a list of the 7 Best Big Company Stocks to Buy Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other big ...